Nikolaj Sten Troelsen

Nikolaj Sten Troelsen

Auto-generated profile, based on publicly available information

Nikolaj Sten Troelsen

Center for Nanomedicine and Theranostics Department of Chemistry Technical University of Denmark Kemitorvet 207 2800 Kongens Lyngby Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
JCJorge Peiró Cadahía
Jorge Peiró Cadahía
VPViola Previtali
Viola Previtali
NTNikolaj S. Troelsen
Nikolaj S. Troelsen
MCMads Clausen
Mads Clausen
A comprehensive review of ROS-activated produg strategies for targeted therapy, including state-of-the-art and future perspectives.

14 November 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
NTNikolaj S. Troelsen
Nikolaj S. Troelsen
ESElena Shanina
Elena Shanina
DGDiego Gonzalez‐Romero
Diego Gonzalez‐Romero
DDDaniela Danková
Daniela Danková
IJIda S. A. Jensen
Ida S. A. Jensen
MCMads Clausen
Mads Clausen

20 January 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
AHAbigail R. Hanby
Abigail R. Hanby
NTNikolaj S. Troelsen
Nikolaj S. Troelsen
TOThomas J. Osberger
Thomas J. Osberger
SKSarah L. Kidd
Sarah L. Kidd
KMKim T. Mortensen
Kim T. Mortensen
DSDavid Spring
David Spring
Herein, we describe the natural product inspired synthesis of 38 complex small molecules based upon 20 unique frameworks suitable for fragment-based screening.

27 April 2020 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
NTNikolaj Sten Troelsen
Nikolaj Sten Troelsen
MCMads Clausen
Mads Clausen

1 August 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NANikolaj S. Andersen
Nikolaj S. Andersen
JCJorge Peiró Cadahía
Jorge Peiró Cadahía
VPViola Previtali
Viola Previtali
JBJon Bondebjerg
Jon Bondebjerg
CHChristian A. Hansen
Christian A. Hansen
MCMads Clausen
Mads Clausen
Methotrexate (MTX) is the standard of care in the treatment of rheumatoid arthritis (RA), a common autoimmune disease that is characterized by chronic inflammation in the synovial membrane of joints. Unfortunately, MTX suffers from high discontinuation rates due to a large variability in efficacy and, in particular, adverse effects. As inflammation is associated with elevated levels of reactive oxygen species (ROS) like H2O2, we propose to improve treatment through site-selective delivery of MTX to inflammatory tissue by use of a H2O2 sensitive MTX prodrug. To establish proof proof-of-concept, two novel H2O2 sensitive, thiazolidinone-based MTX prodrugs were synthesized and evaluated for this purpose. MTX-γ-thiazolidinone (MTX-γ-TZ) exhibited the most promising properties - good to high chemical and metabolic stability, excellent aqueous solubility, while being activated when subjected to patho-physiological concentrations of H2O2. In vivo, MTX-γ-TZ exhibited comparable efficacy to MTX in a murine collagen type II-induced arthritis (CIA) model while treated mice showed indications of reduced toxicity as their body weight decreased less towards the end of the study, compared to the MTX-treated group.

1 April 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
APAsger B. Petersen
Asger B. Petersen
NANikolaj S. Andersen
Nikolaj S. Andersen
GKGleb Konotop
Gleb Konotop
NHNur Hafzan Md Hanafiah
Nur Hafzan Md Hanafiah
MRMarc S. Raab
Marc S. Raab
MCMads Clausen
Mads Clausen